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Loss of T cell homeostasis usually precedes the onset of AIDS. We hypothesized that rapid progressors may be transmitted with HIV-1
that is particularly able to perturb T cell homeostasis. To this end, we have tested two transmitted, syncytium-inducing (SI) viral isolates from
a rapid progressor in two thymus models. One of the isolates (R3A) exhibited markedly rapid kinetics of replication and thymocyte depletion.
These phenotypes mapped to the envelope, as a recombinant NL4-3 virus encoding the R3A envelope had similar phenotypes, even in the
absence of nef. Notably, the viruses with high pathogenic activity in the thymus (R3A and NL4-R3A) did not show enhanced replication or
cytopathicity in PHA-stimulated PBMCs. Furthermore, NL4-R3A did not enhance replication of the coinfected NL4-3 virus in the thymus,
suggesting an intrinsic advantage of the R3A envelope. The R3A envelope showed higher entry activity in infecting human T cells and in
depleting CD4+ thymocytes when expressed in trans. These data suggest that SI viruses with unique envelope functions which can overcome
barriers to transmission may hasten disease progression by perturbing T cell homeostasis.
D 2004 Elsevier Inc. All rights reserved.
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HIV-1 infection is characterized by progressive loss of
CD4+ T cells, loss of T cell homeostasis, and eventual onset
of systemic immunodeficiency (Margolick et al., 1995;
Tersmette et al., 1989). The rate of disease progression is
influenced by both host and viral factors. A strong CTL
response, development of neutralizing antibodies, corecep-
tor polymorphism, HLA heterogeneity, and systemic T cell
activation are all host factors shown to impact the kinetics of
immune exhaustion and viral submission (Borrow et al.,
1994; Letvin and Walker, 2003; Mackewicz et al., 1991;
McCune, 2001; Sousa et al., 2002). In the absence of0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this work.therapy, these host defense mechanisms ultimately fail to
control replication and immunodeficiency ensues.
The nature of transmitted virus has also been shown to
impact disease progression. A typical subtype B HIV-1
infection involves transmission of a macrophage tropic,
CCR5-utilizing isolate across a mucosal or parenteral surface
(Markham et al., 1995; Zhu et al., 1993). These transmitted
viruses are typically not cytopathic or fusogenic to Tcell lines
in vitro, and are therefore termed non-syncytium inducing
(NSI) (Fauci, 1996). In temporal correlation with the onset of
AIDS, emergence of CXCR4-utilizing strains is observed in
about 50% of patients and is thought to contribute to
accelerated disease progression (Richman and Bozzette,
1994; Tersmette et al., 1989). CXCR4-utilizing variants are
typically highly cytopathic and fusogenic in vitro and are thus
termed syncytium-inducing (SI) (Fauci, 1996). While it is
possible that such variants emerge opportunistically in the004) 74–88
Table 1
HIV-1 isolates from a rapid progressor (R3) in the ALIVE cohort
Virus Replication Coreceptor usage
MDMa PBMC CCR5b CXCR4b
R3A + + + +
R3B + + + +
NL4-3c  +  +
a MDM = monocyte derived macrophages.
b Determined by infection of U373 cells expressing CD4 and CCR5 or
CXCR4, and sensitivity to CXCR4- and CCR5-specific inhibitors in
PBMCs and HF-TOC.
c Standard laboratory reference strain used for comparison.
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infected macaques clearly indicate that CXCR4 variants
cause accelerated disease progression due, in part, to altered
cellular tropism (Harouse et al., 1999). Furthermore, this
disease progression has been correlated with distinct lesions
in the thymus of newborn-infected macaques (Reyes et al.,
2004). Factors governing the selective disadvantage of
CXCR4-tropic viruses early in disease and their eventual
emergence remain unclear.
The contributions of viral characteristics to rapid disease
progression in humans are not fully understood. While host
genetic and immune predisposition play a role, the nature of
the transmitted virus could impact disease progression
analogous to what is observed in the SHIV macaque model.
During a normal HIV infection, CXCR4 variants take years
to emerge and often arise before loss of T cell homeostasis
and the onset of AIDS (Philpott, 2003). It is possible that
variants which are cytopathic and have an enhanced ability
to either perturb T cell homeostasis or cause elevated
immune activation could cause accelerated disease progres-
sion if they are able to overcome intrinsic barriers to
transmission (Yu et al., 1998).
The thymus contributes to T cell homeostasis and is
responsible for production of naive T cells, particularly early
in life. Contrary to expectations, the thymus continues to
function throughout life and has shown the capacity to
respond to T cell depletion (McCune et al., 1998; Smith et
al., 2000). Numerous studies have demonstrated thymic
parenchymal damage and involution during HIV-1 infection
(Joshi and Oleske, 1985; Papiernik et al., 1992; Pekovic et
al., 1987; Rosenzweig et al., 1993; Schuurman et al., 1989).
Importantly, HIV infants with impaired thymus functions
show accelerated disease progression (Kourtis et al., 1996).
It is thus possible that disease progression could be affected
by viruses that are particularly able to disturb the thymus,
thereby hampering one arm of T cell homeostasis.
The ALIVE IV-drug user cohort identified six rapidly
progressing patients who developed AIDS within 5 years of
seroconversion (Yu et al., 1998). Three of these rapid
progressors lost T cell homeostasis almost immediately after
infection and were uniquely transmitted with SI viruses that
were both macrophage and T cell tropic (Yu et al., 1998). To
better understand the role of transmitted virus in rapid
disease progression, we have characterized two transmitted
SI HIV-1 isolates obtained from one rapid progressor in this
cohort who demonstrated an early failure of T cell homeo-
stasis. The viruses were obtained at the time of seroconver-
sion and were previously shown to be macrophage-tropic
and SI in vitro. We hypothesized that HIV-1 variants from
this patient may be particularly effective at perturbing T cell
homeostasis, thereby hampering the immune system’s
ability to delay the onset of immunodeficiency. To test this
hypothesis, we characterized the replication and patho-
genesis of the isolates in PBMCs in vitro and in two human
thymus models. We report that both isolates can utilize
CCR5 and CXCR4 and are capable of efficient replicationand CD4+ T cell depletion in PBMCs. One of the isolates,
however, shows astounding levels of replication and
thymocyte depletion in the thymus. The thymus-tropism
of this variant maps to the envelope gene, which functions
in the absence of nef, and intrinsically promotes viral
replication in the thymus. Furthermore, this envelope shows
an enhanced ability to mediate infection of the thymocyte-
like SupT1 cell line and is efficient at depleting CD4+
primary human thymocytes when expressed in trans.Results
Two early isolates from a rapid progressor are dual tropic,
infect macrophages, and show normal kinetics of replication
in stimulated PBMCs
Three of the rapid progressors (R1-3) from the ALIVE
IV-drug user cohort with early loss of T cell homeostasis
were uniquely transmitted with SI variants capable of
replication in both macrophages and T cells (Yu et al.,
1998). We obtained two different isolates (R3A and R3B)
from one of these rapid progressors (R3) which were
generated via coculture of patient PBMCs isolated at the
time of seroconversion with PHA-stimulated allogenic
PBMCs (Yu et al., 1998). Thus, the isolates are representa-
tive of the transmitted virus. We first confirmed macrophage
tropism using peripheral blood monocyte-derived macro-
phages (Table 1). Using U373-Magi cells expressing CD4
and either CCR5 or CXCR4, we found that R3A and R3B
could use both CXCR4 and CCR5 as coreceptors (Table 1).
Both isolates also showed sensitivity to the CXCR4-specific
inhibitor AMD3100 in PBMCs (Table 1 and data not
shown). In addition, we analyzed their ability to use
alternative chemokine receptors in vitro and found that
neither R3A nor R3B was able to significantly use CCR1,
CCR2b, CCR3, CCR4, V28, Bob, Bonzo, or CCR8 (data
not shown).
We next compared the replication kinetics and cytopa-
thicity of R3A and R3B in PHA-activated PBMCs to the
standard CXCR4-utilizing NL4-3 virus (Table 1 and Fig. 1).
R3A and R3B replicated comparably to NL4-3 over a 2-
week time course (Fig. 1A). Fourteen days post-infection,
Fig. 1. Replication and pathogenesis of the R3 isolates in activated PBMCs.
(A) An equal MOI of virus was used to infect 10 million PHA-stimulated
PBMCs. Supernatant was harvested every 3 days and quantitated by reverse
transcriptase (RT) assay. Units for RT activity are derived from densito-
metric quantification and are arbitrary. Standard deviation was calculated
from duplicate samples. Shown is a representative example from three
independent experiments. (B) Depletion of CD4+ cells 14 days after
infection. Cells were harvested and stained for CD4 and CD8. The
percentage of cells gated live by scatter profiles which were CD4+ is
shown. Shown is a representative experiment with duplicate samples.
E.G. Meissner et al. / Virology 328 (2004) 74–8876we measured the extent of CD4+ T cell depletion by FACS
analysis and found that R3A and R3B were less capable of
depleting CD4+ cells than NL4-3 (Fig. 1B), corresponding
with slightly lower viral replication at late time points (Fig.
1A). Therefore, neither R3 isolate shows enhanced repli-
cation or cytopathicity when observed in the context of
PHA-stimulated PBMCs relative to a typical CXCR4-
utilizing virus or to 89.6 and 320.3.1 (Groenink et al.,
1992), two other primary dual-tropic isolates (data not
shown).
R3A exhibits enhanced replication and cytopathicity in the
human thymus
Unlike in vitro stimulated PBMCs, lymphoid micro-
environments in vivo are composed of multiple cell types
and more quiescent cell populations that require unique viral
determinants for HIV replication and pathogenesis (Meiss-
ner et al., 2003; Su et al., 1997). To test if HIV-1 isolates
from this rapid progressor may be particularly capable of
replication and depletion of CD4+ cells in these environ-
ments, we characterized the R3A and R3B isolates using the
human fetal-thymus organ culture (HF-TOC) and SCID-hu
Thy/Liv mouse models.HF-TOC fragments were infected with 100 infectious
units of R3A, R3B, NL4-3, or mock supernatant and were
monitored for HIV replication and thymocyte depletion over
2 weeks. The R3B virus achieved levels of replication that
were comparable to the standard NL4-3 strain. Surprisingly,
R3A showed reproducibly higher levels of replication than
both NL4-3 and R3B throughout the culture period (Fig.
2A). Pathogenesis was assessed by CD4 and CD8 FACS
analysis to determine the extent of viral-mediated CD4 cell
depletion (Figs. 2B–D). NL4-3 and R3B showed similar
levels of depletion of CD4+ thymocytes relative to mock-
infected fragments. In contrast, R3A induced almost
complete depletion of CD4+ cells by 12 dpi, with significant
depletion observable only 4–6 dpi. The percentage of cells
in the live gate defined by scatter profiles paralleled
depletion observed in the CD4+ population (Fig. 2B and
data not shown).
To verify these results, we assessed the replication and
pathogenesis of the R3 isolates in the SCID-hu Thy/Liv
model. SCID-hu Thy/Liv mice were infected with an
equivalent amount of R3A, R3B, NL4-3, or mock super-
natant. Thymocytes were harvested by biopsy each week for
4 weeks after infection, and the level of thymocyte-
associated p24 was measured by ELISA. As in HF-TOC,
R3B replicated comparably to the reference NL4-3 strain,
while R3A replicated to extremely high levels at 1 and 2
weeks post-infection (Fig. 3A). When replication was
normalized to levels of the reference strain NL4-3 within
each experiment, R3A showed significantly higher repli-
cation than NL4-3 and R3B at 2 weeks post-infection (P b
0.05 by the Student’s t test, data not shown). The decline in
viral load of R3A observed at 3 and 4 weeks post-infection
was likely due to depletion of CD4+ thymocytes.
As shown in Fig. 3B, the depletion of thymocytes
followed the peak of replication in the Thy/Liv organ. NL4-
3 and R3B caused thymocyte depletion at 4 wpi, following
their peak replication at 3 wpi. R3A, consistent with its
earlier peak at 1–2 wpi, caused early and significant
depletion at 2–3 wpi, with almost complete ablation of
CD4+ thymocytes by four wpi. These results collectively
indicate that the R3A isolate, which replicates normally in
PBMCs with attenuated depletion of CD4+ cells, shows
tropism for the in vivo thymic microenvironment with a
striking ability to replicate in and deplete CD4+ thymocytes
relative to other SI isolates.
The R3 envelopes recapitulate the replication and
cytopathic phenotype of the parental R3 viruses in the
absence of nef
While both R3A and R3B demonstrated the ability to
replicate in the thymus, R3A was clearly unique in
achieving the highest levels of replication and thymocyte
depletion. We therefore sought to define the viral determi-
nants responsible for this phenotype. We hypothesized that
distinct features of the envelope may be responsible and
Fig. 2. Replication and cytopathicity of the R3 isolates in HF-TOC. In each experiment, fetal thymus fragments were infected with mock supernatant, NL4-3,
R3A, or R3B. (A) Thymocytes were isolated and cell-associated p24 was measured by ELISA. The results from at least three independent experiments are
summarized. (B–C) Isolated thymocytes were stained for CD4 and CD8 and gated by scatter profiles. A representative FACS plot showing pathogenesis
mediated by R3A at 9 days post-infection relative to mock, NL4-3, and R3B is shown. Shown are the percentage of cells gated live or in each quadrant of CD4/
CD8 staining. (D) Pathogenesis of the R3 isolates was summarized by measuring total CD4+ thymocyte depletion. The total percent CD4+ cells was calculated
by adding the % CD4+CD8+ immature thymocytes with the % CD4+CD8 thymocytes of cells gated live by forward and side scatter. The results from at least
three independent experiments are summarized.
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R3A and R3B using PCR of genomic DNA extracted from
the first passage of R3A or R3B-infected PBMCs in our
laboratory (2nd passage overall). PCR products were
subsequently cloned into a retroviral expression vector.
One R3B and eight R3A clones were obtained.
To assess whether the envelope clones were representa-
tive of the original viral isolates, we performed a hetero-
duplex tracking assay (HTA) using a radiolabeled probe
homologous to a portion of the JR-FL V1/V2 region
(Kitrinos et al., 2003). Relative migration of heteroduplexes
is determined by the degree of homology between the query
and probe sequence. The parental R3B isolate was found to
contain one major variant and R3A to contain one major and
one minor variant (Fig. 4A). HTA performed on theenvelope clones verified that each major variant was
represented by at least one clone.
The clones were next tested for envelope expression and
processing. As shown in Fig. 4B, most clones produced the
gp160 and gp120 envelope proteins, while several clones
showed little (R3A #3) or abnormal (R3A #8) expression
(Fig. 4B and data not shown). Clones 1 and 4 for R3A
appeared identical by Western, while clone 2 appeared
smaller, in spite of similar migration by HTA, suggesting the
presence of different isoforms within the R3A population,
which may vary by glycosylation sites.
The cloned envelope genes were next tested for function
using a pseudotyping assay. NL4-luciferase pseudotyped
with each env clone was used to infect the SupT1 cell line
and productive infection was assessed by luciferase assay
Fig. 3. Replication and cytopathicity of the R3 isolates in SCID-hu Thy/Liv
mice. In each experiment, three mice were infected with mock supernatant,
NL4-3, R3A or R3B. (A) Thymocytes were harvested by biopsy each week
for 4 weeks after infection and assessed for HIV replication by quantifying
cell-associated p24 by ELISA. The combined results of three independent
experiments are shown. When replication was normalized to NL4-3 within
each experiment (data not shown), R3A showed a statistically significant
increase in replication relative to R3B and NL4-3 at 2 wpi (*P b 0.05). (B)
Pathogenesis of the R3 isolates was assessed by measuring CD4+
thymocyte depletion as in Fig. 2.
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proved functional for infection in the pseudotyping assay,
while the two misexpressing R3A clones (#3, #8) with faster
HTA migration, possibly corresponding to the minor
variant, proved non-functional for entry (Fig. 4A). We
therefore obtained at least one functional clone for each R3
isolate that represented the major variant of the parental
virus by HTA.
Clone 1 for R3B (GenBank accession no. AY608576)
and clone 4 for R3A (GenBank accession no. AY608577)
were chosen for sequence analysis based on HTA migration
and functionality (Fig. 4C). We chose clone 4 as a
representative species of R3A because it represented two
of three functional clones obtained. Both chosen envelopes
were capable of mediating infection via CCR5 and CXCR4Fig. 4. Cloning and characterization of the R3 envelopes. (A) HTA analysis of th
with the R3 viruses were used for nested PCR and products were cloned into a retro
or of the clones. Resulting products were hybridized to the radiolabeled V1/V2 pro
sequencing gels. Envelope functionality was determined by infecting SupT1 cells w
and processing of the envelope clones were assessed after transfection into A293
Sequence of the R3A and R3B envelopes. The V1–V5 regions and the fusion dom
The space in the V5 region of the R3B sequence indicates a gap.like the parental viruses in U373 cells (data not shown). As
expected, the R3A and R3B envelope sequences were found
to be extremely similar to each other. Their greatest
variation in sequence was in the variable regions, and the
slower migration of the R3B envelope by Western was
consistent with its higher number of potential N-linked
glycosylation sites relative to R3A (26 vs. 25 in gp120).
Given their distinct phenotypes in the thymus, we were
surprised that the V3 loop of R3A and R3B are identical in
amino acid sequence. In contrast, the V1/V2 regions showed
significant differences consistent with the difference
observed in the HTA. Additionally, no differences were
observed in the fusion domain, transmembrane domain, or
in amino acids shown to contribute to the CD4 binding site
(Kwong et al., 1998). The tat sequence in the overlapping
region was identical for the R3A and R3B clones, while the
rev sequences differed by three amino acids. The R3A and
R3B vpu proteins differed at 4 amino acids which are
known to be variant, while the major known functional
motifs (McCormick-Davis et al., 2000) were conserved
(data not shown).
To determine whether the envelope of each R3 virus was
responsible for the phenotype of the parental virus in the
thymus, we tested the functional, sequenced R3A and R3B
envelopes in the background of the NL4-3 proviral genome.
As a result of the cloning strategy (Fig. 5A), nef was deleted
from each recombinant virus, allowing for a strict character-
ization of envelope-dependent replication and pathogenesis.
While both original R3A and R3B isolates express nef,
neither of the NL4 recombinants (NL4-R3A and NL4-R3B)
expresses nef due to the deletion and frameshift introduced
during cloning (Figs. 5A–B).
Replication and cytopathicity of the recombinants were
first assessed in PHA-stimulated PBMCs. Like the parental
viruses, NL4-R3A and NL4-R3B replicated comparably to
NL4-3 and NL4-Dnef, and showed reduced depletion of
CD4+ cells relative to NL4-3 (data not shown). Replication
and pathogenesis of the recombinants in the thymus were
then characterized in HF-TOC as above. As shown in Fig.
6A, replication of the recombinants NL4-R3B and NL4-
R3A in HF-TOC was similar to the parental viruses R3B
and R3A, respectively. NL4-R3B was found to replicate
similarly to NL4-3, while NL4-R3A showed higher levels
of replication. NL4-R3A showed significantly enhanced
replication relative to NL4-3 and NL4-R3B at days 5–7 and
days 8–9 when replication was normalized to NL4-3
replication (P b 0.05, data not shown). The high level of
replication measured by p24 ELISA was paralleled by a
greater extent of integrated HIV proviral DNA, as assessede parental viruses and the clones obtained by nested PCR. PBMCs infected
viral vector. PCR was performed on the V1/V2 region of the original viruses
be from the JR-FL virus. Heteroduplexes were visualized on polyacrylamide
ith pseudotyped virus. NA = not applicable, ND = not done. (B) Expression
T cells and probing of lysates with a polyclonal anti-gp120 antibody. (C)
ains are indicated and the transmembrane domain of gp41 is shown in bold.
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Fig. 5. Generation of NL4-R3 envelope recombinant viruses with deletion of the nef gene. (A) The env gene was digested with EcoR1 and Xho1, which was
added directly at the end of the env ORF during cloning. Ligation of the Env fragment into the endogenous NL4-3 Xho1 site creates a deletion, resulting in a
frameshift that eliminates expression of nef. (B) Infected PBMCs were lysed and probed by Western for gag and nef expression. While the parental R3 viruses
encode nef, the recombinant NL4-R3 viruses do not.
E.G. Meissner et al. / Virology 328 (2004) 74–8880by real time PCR of gag DNA 5 days post-infection (Fig.
6B). Finally, depletion of CD4+ thymocytes by the
recombinants closely paralleled that observed with the
parental viruses, as NL4-R3A caused rapid depletion of
total CD4+ cells (Fig. 6C). This decrease in percent CD4+
cells was paralleled by a decrease in total cell number and
the percent of cells gated live by scatter profiles (data not
shown). In summary, the enhanced replication and cytopa-
thicity of the R3A isolate can be accounted for by its unique
envelope even in the absence of nef.
Our in vitro studies suggested that the R3A and R3B
envelopes were both capable of using CXCR4 and CCR5 to
infect the U373 cell line. To address whether these
coreceptors are partially or exclusively used in HF-TOC,
we performed an infection in the presence of a CXCR4
(AMD3100) and/or a CCR5 antagonist (Tak-779). HF-TOC
fragments were pretreated with AMD3100 and/or Tak-779
before infection and were replenished every other day for 7
days, at which time p24 replication was measured by
ELISA. Either AMD3100 or Tak-779 inhibited replication
of both R3A and R3B in HF-TOC. In addition, replication
was cooperatively reduced (by at least 80%) for both NL4-
R3A and NL4-R3B when both AMD3100 and Tak-779were used (data not shown). These data suggest that both
CXCR4 and CCR5 are used by the R3A and R3B envelopes
in the thymus. Because complete blockage of viral infection
was not observed, it is possible that the doses of coreceptor
antagonist used were insufficient to block viral replication
completely. Additionally, it remains possible that R3B and/
or R3A could use an alternate coreceptor in the thymus in
addition to CXCR4 and CCR5, even though no additional
known coreceptor usage was detected in our in vitro
experiments.
The R3A envelope shows intrinsic, hyper-replicative activity
in the thymus
As noted above, the R3 viruses and the NL4 recombi-
nants did not show enhanced replication or cytopathicity
when observed in activated PBMCs. However, R3A and
NL4-R3A appeared hyperactive in replication and patho-
genesis within the thymus. To test if the R3A envelope does
intrinsically better in the thymus, independent of the
secondary stimulatory events the R3A envelope may
induce, we performed a series of competition experiments
in both PBMCs and HF-TOC.
Fig. 6. NL4-R3A shows enhanced replication and cytopathicity in HF-
TOC. (A) Replication of NL4-3, NL4-R3A, and NL4-R3B in HF-TOC was
measured by p24 ELISA of TOC supernatant. Shown are the combined
results from four independent experiments. When replication was normal-
ized to NL4-3 within each experiment (data not shown), NL4-R3A showed
a statistically significant increase in replication relative to NL4-R3B and
NL4-3 at 5–7 and 8–9 dpi (*P b 0.05 by the Student’s t test). (B) Increased
replication of NL4-R3A as revealed by real time PCR analysis for proviral
DNA. Thymocytes were harvested 5 days post-infection and DNA lysates
was isolated. Real time PCR for the actin gene was used for normalization
and a representative experiment is shown. Results are from one of four
experiments with error bars derived from duplicate samples. (C) Patho-
genesis was assessed as in Fig. 2. Shown are the cumulative results of four
independent experiments.
Fig. 7. NL4-R3A is able to outcompete NL4-3 in the thymus, but not in
activated PBMCs. (A) NL4-3 and NL4-R3A mixed in differing ratios were
used to inoculate activated PBMCs and HF-TOC fragments. Viral super-
natant was harvested every three days and the relative proportion of NL4-
R3A to NL4-3 was determined by HTA (total proportion = 1). Underlined
numbers represent the relative amount of NL4-3 added. (B) The bands in
(A) were quantitated by densitometry. The relative proportion of NL4-R3A
in the total viral population (NL4-3 + NL4-R3A) in each sample was
calculated. Error bars represent data from infections performed in duplicate.
E.G. Meissner et al. / Virology 328 (2004) 74–88 81PBMCs and HF-TOC were infected with NL4-3 alone,
NL4-R3A alone, or coinfected with a mixture of NL4-3 and
NL4-R3A in various ratios as measured by virion-associated
reverse transcriptase activity (Fig. 7). In the thymus, the
most extreme competition gave NL4-3 a 560 to 1 starting
advantage over NL4-R3A. Supernatant was harvested at 0,
3, 6, and 9 days post-infection and the relative amount of
each virus was assessed by HTA followed by densitometric
quantification (Figs. 7A–B). As seen in Fig. 7A, the relativeNL4-R3A and NL4-3 levels were stable in coinfected
PBMCs, indicating their similar replicative capacity. In
stark contrast, NL4-R3A was able to efficiently outcompete
E.G. Meissner et al. / Virology 328 (2004) 74–8882NL4-3 in HF-TOC when applied at a 1:5.6 disadvantage.
NL4-R3A even recovered when applied at a 1:560 dis-
advantage. Results from a similar competition experiment
between NL4-R3B and NL4-R3A yielded similar results in
HF-TOC with NL4-R3A outcompeting NL4-R3B (data not
shown). These competition experiments clearly reveal that
the R3A envelope is selectively capable of efficient
replication within the context of the thymic microenviron-
ment, an advantage that is not observed in activated
PBMCs. In addition, these data indicate that the R3A
envelope functions intrinsically to enhance NL4-R3A
replication, but not the co-infected NL4-3 or NL4-R3B, in
the thymus.
The R3A envelope allows enhanced infection of SupT1 cells
and demonstrates cytopathicity towards primary human
CD4+ thymocytes when expressed in trans
To address the potential mechanism of elevated repli-
cation and cytopathicity of the R3A envelope, we used
NL4-luciferase pseudotyped with R3B or R3A envelope and
infected SupT1 cells to measure their relative ability to
mediate viral entry. When equal amounts of total virion
were used, we found that R3A-pseudotyped virus was
significantly more efficient at mediating entry in SupT1
cells than R3B-pseudotyped virus (Fig. 8A). This may
explain, in part, how the R3A envelope is capable of
achieving enhanced replication in the thymus.
We next used an in vitro coculture system to assess a
possible mechanism for the enhanced cytopathicity of the
R3A envelope. Expression of each envelope construct or a
vector in 293T cells, followed by coculture with primary
human thymocytes, allowed us to address the effect of
each envelope when exposed in trans. We measured
depletion of total CD4+ thymocytes (including
CD4+CD8+ and CD4+CD8 thymocytes) 2 days after
coculture relative to CD4CD8+ thymocytes, which are
relatively unaffected by envelope exposure (Figs. 8B–D).
While R3B was capable of depleting CD4+ cells relative to
vector-transfected cells, R3A was significantly more
efficient in this depletion. Together, these data suggest
that enhanced entry and/or fusion of the R3A envelope in
thymocytes may contribute to its cytopathic phenotype. It
will be interesting to determine whether the ability to
enhance viral entry and the ability to deplete CD4+
thymocytes in trans are linked or are separable functions
of the R3A envelope.Fig. 8. The R3A envelope mediates enhanced entry into SupT1 cells and enhanced
(A) NL4-luc was pseudotyped with either envelope and virus was used to infect S
was measured. Shown is one of three experiments with infections performed in trip
D) 293T cells transfected with vector or an envelope construct were irradiated
thymocytes. Forty-eight hours post-coculture, cells were harvested and analyzed
thymocytes, with the percentage of cells in the live gate shown. (C) Cytopathicity
(CD4+CD8+ and CD4+CD8) to CD4CD8+ thymocytes. The percentages in ea
bars represent standard deviation from samples run in duplicate.Discussion
Loss of T cell homeostasis evidenced by decreasing
CD4 and CD8 T cells is strongly associated with the onset
of AIDS (Margolick et al., 1995). To help maintain T cell
homeostasis, the thymus functions throughout adult life to
populate the periphery with naive CD4 and CD8 T cells
(Douek et al., 1998). Furthermore, thymic production of
naive cells is impaired in HIV-1 patients and suppression
with HAART therapy allows a partial recovery of this
production (Douek et al., 1998). In the ALIVE IV-drug
user cohort, 3 of 105 seroconverters showed rapid loss of
T cell homeostasis and progression to AIDS within 5
years, associated with transmission of SI HIV isolates (Yu
et al., 1998). We hypothesized that these rapid progressors
may be transmitted with isolates that are particularly
capable of perturbing T cell homeostasis, including thymic
potential. Herein, we characterize two independent isolates
from a rapid progressor and identify a unique isolate,
which shows a striking ability to selectively replicate in
and deplete CD4+ thymocytes. Furthermore, this pheno-
type maps to the viral envelope and is observable in the
absence of nef.
Both isolates from the rapid progressor could utilize both
CXCR4 and CCR5. CXCR4-utilizing variants are usually
not transmitted and typically emerge late in disease in
correlation with the onset of AIDS. In cases where trans-
mission of CXCR4 variants does occur, these variants are
capable of productively infecting macrophages (Koning et
al., 2001; Naif et al., 2002). Consistent with these findings,
the isolates from patient R3 showed macrophage tropism in
addition to their ability to use CXCR4 (Table 1 and
(Scarlatti et al., 1997; Yi et al., 2003)). Because the R3
viruses can use CCR5 and CXCR4, it is unsurprising that
these isolates should be capable of replication within the
CXCR4-rich human thymus (Camerini et al., 2000; Glush-
akova et al., 1998; Taylor et al., 2001). However, our most
intriguing finding was the identification of the highly
thymus-tropic R3A isolate. This strain was particularly
capable of replication and depletion within the thymus, an
advantage that was not apparent when characterized relative
to other strains in stimulated PBMCs or in the tonsil-lymph
node organ culture (data not shown). Both stimulated
PBMCs and the lymph node organ culture are permissive
for replication by the tissue-culture adapted HXB2 virus,
while the thymus is not, demonstrating the quiescent nature
of the thymic microenvironment (Glushakova et al., 1998;cytopathicity towards primary human thymocytes when expressed in trans.
upT1 cells. Cells were lysed at 72 h post-infection and luciferase expression
licate. Luciferase expression was normalized to input p24 (total virions). (B–
24 h post-transfection and cocultured with freshly isolated human fetal
by FACS analysis. (B) Forward and side scatters were used to gate on live
for CD4+ thymocytes is expressed as the ratio of total CD4+ thymocytes
ch gate and the ratio are shown. (D) Shown is one of four experiments. Error
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X4/R5 dual tropic isolates which emerged during HIV
infection do not show such enhanced pathogenesis in thethymus. For example, 89.6 replicated inefficiently in the
thymus (unpublished observation) and 320.3–1, another
primary X4/R5 isolate which emerged during the transition
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demonstrates NL4-like levels of replication and patho-
genesis in the thymus like R3B (unpublished observation).
This suggests that R3A is particularly capable of efficient
replication and pathogenesis within the thymus micro-
environment, potentially including cell-to-cell spread. It
will be interesting to assess whether R3A-like envelope
species can be found in other rapid progressors with early
loss of T cell homeostasis, or from patients with standard
disease progression around the time of loss of T cell
homeostasis.
The phenotype of the R3A virus was mapped to its
envelope gene. While several different envelopes were
obtained from the R3A isolate, the one chosen for analysis
appears representative based on HTA analysis, functionality
in vitro, and on its phenotype in the thymus. Although we
are unable to completely rule out a unique effect of the R3A
vpu or rev genes within the NL4-R3A recombinant, the
R3A sequences were highly similar to the NL4-3 and R3B
vpu and rev genes (data not shown).
Nef has previously been shown to be required for optimal
replication and pathogenesis of the NL4-3 and JR-CSF
isolates in the thymus (Jamieson et al., 1994). We have
previously reported that a CXCR4-utilizing primary enve-
lope which has evolved in vivo from the lab-adapted HXB2
strain is sufficient to allow replication in the thymus in the
absence of nef, but with attenuated cytopathicity (Miller et
al., 2001). Furthermore, we demonstrated that restoring nef
in the virus enhances cytopathic activity without affecting
its replication levels (Duus et al., 2001). We now
demonstrate that an envelope without nef is capable of
achieving astounding levels of replication and pathogenesis
in the thymus. This suggests that inherent properties of the
envelope, independent of coreceptor usage, can dramatically
affect the success of viral replication and pathogenesis in the
thymus organ. Furthermore, we demonstrate that coinfection
of the thymus with NL4-R3A and NL4-3 led to efficient
outgrowth of NL4-R3A and did not enhance NL4-3
replication. This suggests that inherent properties of the
R3A envelope are responsible for efficient replication in the
thymus, rather than a generally altered cytokine milieu.
To address the possible mechanism for the phenotype of
the R3A envelope in the thymus, we performed several in
vitro experiments to uncover any advantage the R3A
envelope may provide for enhancing either replication or
cytopathicity. We demonstrate that the R3A envelope allows
for more efficient entry than R3B in the thymocyte-like
SupT1 cell line using pseudotyped virus (Fig. 8A). To
assess cytopathicity, we attempted to express envelope
within thymocytes, but were unable to achieve sufficient
levels of transduction with our retroviral envelope expres-
sion vector (data not shown). However, we did find that
R3A is more cytopathic to CD4+ thymocytes when
expressed in trans in a coculture experiment (Fig. 8B).
When infectivity and cytopathicity were assessed in
stimulated PBMCs, R3A was found to have a similaradvantage over R3B, suggesting that this advantage is not
specific to thymocytes in vitro (data not shown). These data
point to an intrinsic advantage for the R3A envelope which
may allow for more efficient or extensive interaction with T
cells relative to the R3B envelope. Studies are ongoing to
further elucidate how intrinsic properties of the R3A
envelope may allow for its success in the thymus. In
particular, we are interested in whether the R3A envelope
shows an enhanced ability to mediate cell to cell trans-
mission or activation of relatively quiescent thymocytes,
two of the most obvious means by which the stimulated
PBMC environment differs from the thymus.
The R3A and R3B env genes are highly similar in
sequence yet show distinct phenotypes, despite both being
primary, SI isolates from the same patient. The exact
relationship of these two viruses from the perspective of
evolution within the patient is unclear, although both were
isolated from PBMCs obtained around seroconversion. Of
particular interest is that the envelopes have identical V3
loops, can both utilize CXCR4 and CCR5, and do not
appear utilize any of the alternative HIV coreceptors (Table
1 and data not shown). Study of these two envelopes should
allow for fine dissecting of the region and mechanisms of
enhanced HIV replication and pathogenesis in the thymus.Materials and methods
Viral isolates and HIV production
The two R3 viruses were obtained as previously
described (Yu et al., 1998). Both R3A and R3B were
derived from cryopreserved blood obtained from patient R3
around the time of seroconversion.
The second PBMC passage of each R3 virus was
amplified for further study using PHA-stimulated PBMCs
cultured in 10 U/ml IL-2, with supernatant changed and
collected daily as previously described (Su et al., 1995). For
NL4-3 and the NL4-R3 recombinants, an equal amount of
proviral DNA was transfected into A293T cells using
Effectene (Qiagen) per the manufacturer’s protocol and
the supernatant was used to infect PHA-stimulated PBMCs.
Infectious titers were determined by MAGI assay using U-
373-MAGI-CXCR4 glioblastoma cells as previously
described (Miller et al., 2001; Vodicka et al., 1997). Reverse
transcriptase activity for the competition experiments was
quantitated using a previously described P33 based incor-
poration assay (Resch et al., 2002).
Coreceptor usage
Primary coreceptor usage was determined using U-373-
MAGI cells expressing either CCR5 or CXCR4. To test for
alternative coreceptor usage, we infected GHOST cells
expressing either CCR1, CCR2b, CCR3, CCR4, CXCR4,
Bob, Bonzo, V28, CCR8, or CCR5 with high titer virus
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were analyzed by flow cytometry (FACS) for GFP
expression. While GFP+ cells were readily detectable using
both CXCR4 and CCR5 expressing cells, we saw no
significant signal above background when GHOST cells
expressing the other chemokine receptors were used. For
blocking experiments in the human thymus using
AMD3100 (Bridger et al., 1995; De Clercq et al., 1994;
Hendrix et al., 2000) and Tak-779 (Baba et al., 1999),
thymus fragments were incubated with antagonists for 4 h
before infection.
Human fetal-thymus organ culture (HF-TOC) assays
The procedure for HF-TOC has been previously
described (Bonyhadi et al., 1995; Miller et al., 2001).
Human fetal thymuses (19 to 24 gestational weeks) were
dissected into approximately 2-mm3 fragments using a
dissecting microscope. 5–6 fragments were placed on
organotypic culture membranes (Millipore) underlaid by
media (RPMI with 10% fetal bovine serum, 50 Ag of
streptomycin/ml, 50 U of penicillin G/ml, 1 MEM
vitamin solution [Gibco/BRL], 1 insulin-transferrin-
sodium selenite medium supplement [Sigma], and beta-
mercaptoethanol), in 6-well tissue culture plates. An equal
amount of virus (100–800 IU) in 15 Al of supernatant from
infected PHA-stimulated PBMCs or mock supernatant was
applied to each fragment. Viral and mock supernatant
produced from the same PBMC donor were used within
each experiment. Fragments were cultured at 37 8C in 5%
CO2 for 10 to 12 days with daily changes of culture
media. Thymocytes were teased out of the fragments using
pestles (Bellco Co.) and analyzed as described below by
FACS. Supernatant was stored for assessment of p24
production.
Infection of SCID-hu Thy/Liv mice
SCID-hu Thy/Liv mice were constructed and infected as
previously described (Krowka et al., 1991; McCune et al.,
1988; Su et al., 1995). Briefly, HIV-1 produced from PHA-
activated PBMCs or mock supernatant was used to infect
each graft. Approximately 2000 IU in 50 Al was used for
each infection. Each week after infection, a biopsy of the
thymus was removed and assessed for viral replication by
p24 ELISA and viral pathogenesis by FACS staining.
Quantification of viral replication
Cell lysates or HF-TOC supernatant were prepared in
PBS-1% Triton X-100. p24 production was measured using
an Alliance p24 ELISA kit (Perkin Elmer). Levels of
proviral integration were assessed by TaqMan real-time
PCR for Gag DNA using primers and probe which have
been previously described (Douek et al., 2002). Approx-
imately 10,000 thymocytes from infected HF-TOC frag-ments were pelleted and lysed in 50 Al of Florence Buffer
(25 Al Florence A: 100 mM KCl, 10 mM Tris HCl pH 8.3,
2.5 mM MgCl2; 25 Al Florence B: 10 mM Tris HCl pH 8.3,
2.5 mM MgCl2, 1% Tween 20, 1% NP40, 200 Ag Proteinase
K added fresh). Lysis was performed at 60 8C for 1 h
followed by 95 8C for 10 min. Input DNA was normalized
using actin real-time PCR with the following primers and
probes: actinF: (5V-TCACCCACACTGTGCCCATC-
TACGA-3V), actinR: (5V-CAGCGGAACCGCTCATTGC-
CAATGG-3V), and actin probe (5V-VIC-ATGCCCTCCCQ
CCATGCCATCCTGCGT-TAMRA-3V).
Flow cytometry analysis
Thymocytes isolated from either SCID-hu Thy/Liv
biopsies or HF-TOC fragments were stained with CD4-PE
and CD8-TC (Caltag) in PBS-2% fetal bovine serum,
washed, and resuspended in PBS-1% formaldehyde. Viral
pathogenesis was assessed by calculating the total percent-
age of cells that stained positive for CD4, including both
CD4+CD8+ immature and CD4+CD8 mature thymocytes.
Cloning and sequencing of the envelope genes and
construction of NL4-R3 recombinant viruses
Envelope genes were amplified from DNA prepared
from an early passage of infected PBMCs as previously
described (Kirchhoff et al., 1999). Nested PCR was
performed to generate amplicons suitable for cloning. The
outer primers have been previously described: VPRF (5V-
ATGGAACAAGCMCCRGMAGACCA-3V; positions 5559
to 5581) and LTRR (5V-GACTACGGCCGTCTGAGG-
GATCTCTAGYTACCA-3V; positions 9689 to 9657)
(Kirchhoff et al., 1999). The first round of PCR was
performed using high fidelity Pfu polymerase (Stratagene).
Second round PCR was performed using the primers E5I (5V-
TATGAAACTTATGGRGATACTTGGGCAGG-3V; posi-
tions 5697 to 5725) and EnvR (5V-CACTACTTTTT-
GACCTCGAGCCACCCATCTTATAGC-3V; positions
8814 to 8779). Positions are listed relative to the NL4-3
genome. An artificially added Xho1 site added to EnvR is
highlighted in bold. A 20:1 ratio of Taq polymerase (Sigma)
to Pfu was used for the second round of PCR. Amplicons
3.1 kb in size were gel extracted (Qiagen), digested with
EcoR1 and Xho1, and ligated into a retroviral expression
vector (Coffield et al., 2003).
The HIV-1 env genes were sequenced entirely on both
strands using a primer walking method on an automatic
sequencer ABI 3100 (Applied Biosystems Inc., Foster City,
CA)(Gao et al., 1996). Primary sequence contigs were
assembled and edited with the Sequencher program (Version
4.0, Gene Codes Corp., Ann Arbor, MI).
To prepare NL4-3 recombinant viruses, the envelope
expression vectors were digested with EcoR1 and Xho1 and
ligated to the similarly digested NL4-3 backbone. Ligations
were transformed into STBL2 competent cells (Invitrogen)
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digest and sequencing. Because of the Xho1 site engineered
in the 3V inner PCR primer (EnvR), nef was deleted from
each recombinant virus as shown in Fig. 5A. Nef was
detected by Western using a polyclonal rabbit antibody
(kindly provided by Ronald Swanstrom, UNC) and gag was
detected using a monoclonal anti-p24 hybridoma obtained
from the NIH AIDS Research and Reference Reagent
Program (Chesebro et al., 1992).
Heteroduplex tracking assay
The heteroduplex tracking assay was performed as
previously described (Kitrinos et al., 2003). Briefly, viral
RNA from the second PBMC amplification was purified
using the Qiagen RNA viral miniprep kit and was used as
substrate for RT-PCR using Titan reverse transcriptase. The
V1/V2 region was amplified using the following primers:
V1 (5V-TTATGGGATCAAAGCCTAAAGCCATGTGTA-3V),
V2-(5V-CCTAATTCCATGTGTACATTGTACTGTGCT-3V).
The same fragment was also amplified from each cloned
envelope. Amplified products were hybridized with the
radiolabeled JR-FL probe and resolved on non-denaturing
6% polyacrylamide gels.
Envelope expression and pseudotyping assay
Each retroviral construct encoding an HIV envelope was
transfected into A293T cells with NL4-luciferase in 6-well
plates. NL4-luc contains a frameshift deletion in env and
encodes the luciferase gene in the nef open reading frame
(Connor et al., 1995). Twenty-four hours post-transfection,
media were changed to DMEM-2% FBS and cells were
cultured at 32 8C. Forty-eight hours posttransfection, virus
was harvested and debris was removed by low-speed
centrifugation (200  g for 5 min). An equivalent amount
of viral p24 was added to 500 Al of RPMI containing
200,000 SupT1 cells and 8 Ag/ml of polybrene. Cells and
virus were incubated at 25 8C for 20 min and were then
centrifuged at 2000  g for 3 h. Forty-eight hours post-
transduction, cells were lysed and assayed using the
Luciferase Assay System (Promega).
To detect envelope expression and processing, envelope
constructs were transfected into A293T cells and harvested
after 48 h. Lysates were prepared per standard protocol and
100 Ag of protein was loaded onto a 6% SDS-polyacryla-
mide gel. Nitrocellulose membranes were probed with anti-
gp120 SF-2 (Env 2–3) (Haigwood et al., 1990) followed by
mouse anti-goat IgG-HRP (1:10,000 from Santa Cruz
Biotechnology).
Expression of envelope in trans with primary human
thymocytes
A293T cells in a 48 well plate (30,000 seeded the day
before) were transfected with an equal amount of vector,R3B, or R3A retroviral expression vectors which also
encode GFP under the PGK promoter. Twenty-four hours
post-transfection, cells were irradiated with 3000 gy to stop
cellular division. Equivalent levels of transfection were
verified by assessing GFP expression by FACS. 200,000
freshly isolated human thymocytes were added to each well
and coculture was allowed to proceed for 48 h. Wells were
harvested and stained with CD4-PE and CD8-TC. The
relative amount of CD4+ depletion was determined by
gating on live thymocytes and normalizing to CD8+ cells as
an internal control.Acknowledgments
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